Institutional members access full text with Ovid®

Share this article on:

Lymph Node Staging in Gastric Cancer: Is Location More Important Than Number?: An Analysis of 1,038 Patients

Karpeh, Martin S. MD*; Leon, Larry PhD; Klimstra, David MD; Brennan, Murray F. MD*

Scientific Papers

Objective To compare the impact of staging systems on the survival of 1,038 patients with gastric cancer undergoing resection for cure in a North American center.

Summary Background Data In 1997, the American Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer redefined N stage in gastric cancer. The number of involved nodes rather than their location defines N, and a minimum of 15 examined lymph nodes is recommended for adequate staging. In the 1988 AJCC N-staging system, N1 and N2 node metastases were defined as within 3 cm or more than 3 cm of the primary; the 1997 AJCC N stages were defined as N1 = 1 to 6 positive nodes, N2 = 7 to 15 positive nodes, and N3 = more than 15 positive nodes.

Methods Between 1985 and 1999, 1,038 patients underwent an R0 resection. Median and 5-year survival rates were compared and the Kaplan-Meier method was used to estimate median survival.

Results The location of positive nodes did not significantly affect median survival when analyzed by the number of positive nodes. In contrast, the number of positive lymph nodes had a profound influence on survival. The new N categories served as a better discriminator of median survival when 15 or more nodes were examined. Survival estimates for stages II, IIIA, and IIIB were significantly influenced by examining 15 or more nodes.

Conclusion The number of positive nodes best defines the prognostic influence of metastatic lymph nodes in gastric cancer. Survival estimates based on the number of involved nodes are better represented when at least 15 nodes are examined.

From the Departments of *Surgery, †Biostatistics, and ‡Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: Martin S. Karpeh, MD, Gastric & Mixed Tumor Service, Dept. of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Presented at the 120th Annual Meeting of the American Surgical Association, April 6–8, 2000, The Marriott Hotel, Philadelphia, Pennsylvania.

Supported by a grant from the Lawrence M. Gelb Foundation.

Accepted for publication April 2000.

© 2000 Lippincott Williams & Wilkins, Inc.